Clinical trials: Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
This is a multi-center, open-label study evaluating pharmacokinetics of TRULANCE® (plecanatide) in breast milk of lactating women treated with TRULANCE
- Trial name
- NCT03551873
- Testing
- Plecanatide
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
This is a study of efficacy and safety of Plecanatide in pediatric subjects aged 12 to < 18 years diagnosed with Chronic Idiopathic Constipation.
- Trial name
- NCT03120520
- Testing
- Plecanatide
- Where
- 36 sites in United States
- Volunteers
- 124 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
The primary objective of this study is to assess the potential of LINZESS® (linaclotide) treatment to induce the development of anti-drug antibodies (ADAs).
- Trial name
- NCT02590432
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories
Chronic Idiopathic Constipation
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
- Trial name
- NCT01919697
- Testing
- Plecanatide
- Where
- 220 sites in United States, Canada
- Volunteers
- 2,370 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic…
- Trial name
- NCT01429987
- Testing
- plecanatide
- Where
- 121 sites in United States
- Volunteers
- 951 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
12-Week Study of Plecanatide for CIC (The National CIC3 Study)
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
- Trial name
- CIC (NCT02122471)
- Testing
- Plecanatide
- Where
- 167 sites in United States
- Volunteers
- 1,410 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
Lubiprostone for Treatment of Chronic Idiopathic Constipation
The purpose of this study was to evaluate the efficacy and safety of oral administration of lubiprostone 24 μg twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.
- Trial name
- NCT02695719
- Testing
- Lubiprostone
- Where
- 5 sites in South Korea
- Volunteers
- 156 people
- Sponsor
- Takeda
Chronic Idiopathic Constipation
Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals
This is a study intended to evaluate the efficacy and safety of the vibrating capsule versus sham non-vibrating capsule on spontaneous bowel movement, in aiding reliving Constipated Individuals
- Trial name
- NCT02030756
- Testing
- vibrating capsule
- Where
- 18 sites in United States, Israel
- Volunteers
- 144 people
- Sponsor
- Vibrant Ltd.
Chronic Idiopathic Constipation
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
The objective of this trial was to determine the efficacy and safety of linaclotide 72 ug administered once daily to patients with chronic idiopathic constipation (CIC).
- Trial name
- NCT02291679
- Testing
- Linaclotide
- Where
- 95 sites in United States
- Volunteers
- 1,223 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Chronic Idiopathic Constipation
Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation
Safety and Tolerability Extension Trial for Patients with Chronic Idiopathic Constipation (CIC)
- Trial name
- NCT01895543
- Testing
- Elobixibat 10 mg
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 411 people
- Sponsor
- Ferring Pharmaceuticals
Chronic Idiopathic Constipation
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.
- Trial name
- NCT01827592
- Testing
- Elobixibat 10 mg, Elobixibat 5 mg
- Where
- 94 sites in United States, Belgium and 8 more
- Volunteers
- 376 people
- Sponsor
- Ferring Pharmaceuticals
Chronic Idiopathic Constipation
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
12 Week Efficacy and Safety Trial Followed by a 4 Week Withdrawal Period for Patients with Chronic Idiopathic Constipation.
- Trial name
- NCT01833065
- Testing
- Elobixibat 10 mg/day, Elobixibat 5 mg/day
- Where
- 97 sites in United States, Brazil and 10 more
- Volunteers
- 314 people
- Sponsor
- Ferring Pharmaceuticals
Chronic Idiopathic Constipation
Elobixibat Colonic Motor Function Study
This is a randomized trial of 36 otherwise healthy patients with chronic idiopathic constipation. The purpose of the study is to compare the effects of daily single-dose oral elobixibat and placebo for 7 days on colonic motor…
- Trial name
- NCT02392546
- Testing
- elobixibat
- Where
- United States
- Sponsor
- Ferring Pharmaceuticals
Chronic Idiopathic Constipation
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation
This will be a multi-center, randomized, double-blind, placebo-controlled study of YKP10811 capsules in patients with chronic idiopathic constipation.
- Trial name
- NCT01989234
- Testing
- YKP10811
- Where
- 69 sites in United States
- Volunteers
- 334 people
- Sponsor
- SK Life Science, Inc.
Chronic Idiopathic Constipation
Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation
The objective of this study is to evaluate the clinical equivalence and safety of the test formulation of Lubiprostone 24 mcg capsules manufactured by Dr Reddy's Laboratories Ltd compared to the marketed formulation AMITIZA® …
- Trial name
- NCT01674530
- Testing
- Lubiprostone
- Where
- 93 sites in United States
- Volunteers
- 909 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Chronic Idiopathic Constipation
A Exploratory Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)
The purpose of this study is to evaluate the efficacy and safety of KWA-0711 in Chronic Idiopathic Constipation (CIC) patients.
- Trial name
- NCT01600001
- Testing
- KWA-0711
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Chronic Idiopathic Constipation
Evaluation of Clinical Equivalence Between Two Lubiprostone Products
The objective of this study is to evaluate the clinical equivalence and safety of the Test formulation of lubiprostone 24 mcg capsules compared to the marketed formulation AMITIZA® (lubiprostone) 24 mcg capsules (Sucampo…
- Trial name
- NCT01372423
- Testing
- Lubiprostone
- Where
- 79 sites in United States
- Volunteers
- 808 people
- Sponsor
- Anchen Pharmaceuticals, Inc
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available…
- Trial name
- NCT00511771
- Testing
- Tegaserod
- Sponsor
- Novartis